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A 28 year-old male with single ventricular heart disease status post Fontan 
palliation and subsequent placement of left ventricle to ascending aorta (LV-AAo) valved 
conduit developed ascites and edema. Diagnostic catheterization revealed elevated 
ventricular end diastolic pressures (EDP) secondary to severe LV-AAo conduit 
regurgitation. Given the unique anatomy, surgical access via the right axillary artery 
provided optimal route for transcatheter valve implantation (TVI) within the conduit. The 
procedure resulted in significant hemodynamic improvement with no complications.  
 
INTRODUCTION 
Single ventricle patients with declining or failing Fontan circulations often have 
limited interventional options for improving overall hemodynamics and functional status 
(1,2). The off-label use of FDA approved transcatheter valves provides a relatively new 
therapeutic option for patients with palliated complex congenital heart disease (3,4). We 
describe the innovative use of transcatheter valve implantation (TVI) in a failing Fontan 
patient using a hybrid surgical vascular access approach. 
 
CASE HISTORY 
A 28 year-old male with d-transposition of the great arteries, hypoplastic right 
ventricle (RV), ventricular septal defect (VSD) and straddling tricuspid valve underwent 
pulmonary artery banding at one year of age followed by a classic Fontan with pulmonary 
artery ligation at age 2. Four years following his Fontan operation, the patient underwent 
placement of a 20 mm valved homograft conduit from the left ventricle to ascending aorta 
(LV-AAo) due to progressive severe restriction of the VSD and outflow to the aorta. At 22 
years of age, he developed multiple atrial arrhythmias and underwent a revision of his 
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Fontan with a 24 mm intra-atrial conduit, Maze procedure and placement of an epicardial 
pacemaker system. Preoperative catheterization prior to Fontan revision demonstrated no 
conduit regurgitation and minimal gradient (peak systolic ejection gradient 5 mmHg). As a 
result, the conduit was not replaced at that time. Six years following his Fontan revision, he 
developed symptoms of abdominal ascites and lower extremity edema. Given his new and 
progressive symptoms, the patient was referred to the catheterization laboratory. 
Hemodynamic evaluation revealed mean Fontan pressures of 25 mmHg secondary to 
elevated RV and LV end diastolic pressures (EDP) of 22 and 21 mmHg, respectively. The 
peak systolic ejection gradient across the conduit was 10 mmHg (Figure 1). The heavily and 
circumferentially calcified LV-AAo conduit had severe regurgitation (Figure 2). The patient 
was an extremely high-risk surgical candidate secondary to his numerous prior 
sternotomies, high Fontan pressures, severe diastolic dysfunction, and calcified conduit 
with close proximity to the sternum. As a result he was referred back to the catheterization 
laboratory two months later for TVI within the LV-AAo conduit.  
The LV-AAo conduit inserted on the leftward aspect of the ascending aorta following 
the lesser curve of the transverse arch. This created an almost 180 degree turn from the 
transverse arch to the distal insertion point of the LV-AAo conduit and precluded 
transcatheter valve delivery from a femoral arterial approach. In addition, the proximal LV-
AAo conduit takeoff was from the LV apex with an oblique orientation to the ventricle, 
which precluded transapical delivery approach. Vascular surgery was consulted to provide 
access via the right axillary artery. Consent for off-label use of a humanitarian device was 
obtained. 
An 8 mm Dacron® graft was anastomosed at an oblique angle directly to the right 
axillary artery, which provided the most direct approach to the LV-AAo conduit via the right 
innominate artery (Figure 3). The distal end of the tube graft was clamped with a vascular 
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clamp for hemostasis and the catheterization was performed via direct puncture through 
the anterior aspect of the Dacron® graft. Once the conduit was accessed, a 20 mm x 82 mm 
Endurant IITM stent graft (Medtronic, Minneapolis, MN) was inserted using the 16 French 
Sentrant sheath (Medtronic, Minneapolis, MN). The stent graft was placed within the heavily 
calcified LV-AAo conduit prior to angioplasty to protect from potential catastrophic rupture 
secondary to its position within the high pressure systemic circulation. The stent graft also 
prevented potential calcific embolization/stroke as a result of anticipated aggressive 
conduit dilation. The calcified conduit created a very rigid tube which measured 18-20 mm 
along the entire course with little to no pulsatility. Therefore, we did not feel additional 
presenting was necessary and proceeded directly to TVI. A Melody Transcatheter 
Pulmonary Valve® (TPV) (Medtronic, Minneapolis, MN) was implanted within the LV-AAo 
conduit on a 20-mm Ensemble® Transcatheter Valve Delivery System (Medtronic, 
Minneapolis, MN) entirely within the distal end of the stent graft. Due to the significant 
residual narrowing within the Melody TPV following delivery, the entire length of the stent 
graft and Melody valve was dilated using a 20 mm x 2 cm Atlas Gold balloon (BARD 
Peripheral Vascular, Tempe, AZ) with effective relief of the stent narrowing (Figure 4). Post-
procedural LV EDP dropped considerably to 10 mmHg and the LV-AAo conduit peak systolic 
ejection gradient was unchanged at 11 mmHg. Angiography demonstrated no residual LV-
AAo conduit insufficiency and no perivalvar leak (Figure 5). The axillary artery access site 
was repaired and wound site closed. The patient tolerated the procedure well without 
complication and was discharged to home the following day. 
 
DISCUSSION  
We report the use of a transcatheter valve to treat a failing Fontan patient secondary 
to LV-AAo conduit insufficiency via a hybrid surgical approach. There are few publications 
Page 4 of 24
Catheterization and Cardiovascular Interventions
Catheterization and Cardiovascular Interventions













describing transcatheter valve placement within the systemic semilunar valve position in 
patients with complex congenital heart disease (5-7). The approaches reported include 
hybrid transapical, cutdown on the innominate artery, and percutaneously via femoral or 
internal jugular veins. Given the patient’s unique anatomy, a hybrid surgical approach via a 
vascular graft provided an ideal approach for intervention in our patient. This approach has 
been utilized in adult patients to facilitate the implantation of transcatheter aortic valves 
and catheter-based Impella® left ventricular assist devices (ABIOMED, Inc. Danvers, MA) 
(8,9). In addition to limiting the injury of the axillary artery, the tube graft provided 
additional vascular length for manipulation of the 100 cm long delivery system. 
The Melody TPV is made from a bovine jugular venous valve which has naturally 
deep commissures allowing for competency in non-circular outflow tracts. The valve is 
supported by a platinum/iridium frame which is highly malleable and can conform to 
irregular conduits (10). We were uncertain of the final configuration and long-term 
diameter of the heavily calcified LV-AAo conduit in this patient and felt the Melody TPV 
would function better than a Sapien Valve (Edwards Lifesciences Corporation, Irvine, CA) in 
a possible elliptical configuration and in a generally smaller outflow diameter. Conduit tear 
is a known risk for TVI and was the most common serious adverse event reported in the 
one-year follow-up of the Melody TPV multicenter Post-Approval Study (11). Heavily 
calcified conduits are at risk for rupture and have been successfully treated with covered 
stents such as the covered Cheatham Platinum stent (NuMED Inc., Hopkinton, NY) (11-13). 
The calcium deposits within the LV-AAo conduit circumscribed its entire length and would 
have extended beyond a single covered stent. Deployment of the stent graft within the 
patient’s conduit prior to any intervention mitigated the bleeding risks from conduit 
rupture in the high pressure systemic circulation and protected against possible calcific 
embolization from the heavily calcified conduit. The stent graft was not used for typical 
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Melody “pre-stenting” as is standardly performed in RV-PA conduits. The conduit stenosis 
provided an optimal landing zone for the transcatheter valve remote from the coronary 
arteries. The hybrid procedural approach coupled with the off-label use of the aortic stent 
graft and Melody TPV resulted in successful and uncomplicated treatment in this high-risk 
surgical patient.  
Although the Melody TPV has performed well relatively high pressure circulations, 
the long term durability is not known and remains a concern in these off-label uses (5,14). 
With the development of smaller diameter and more easily steerable transcatheter delivery 
systems, future re-intervention from the percutaneous femoral arterial approach may be 
possible. However in the absence of this technology, a similar well-planned hybrid approach 
remains a viable option for TVI in patients with complex congenital heart disease. 
 
CONCLUSION 
Innovative off-label use of transcatheter valve therapy can be used to treat high-risk 
patients, including failing Fontan patients that have limited medical and surgical options. 
Hybrid surgical approaches should be considered to provide the safest and most direct 
routes for TVI. 
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Figure 1: Illustrative diagram depicting the patient’s anatomy and hemodynamic 
measurements obtained during diagnostic catheterization. Ventricular pressures are noted 
as systolic/end diastolic pressure. m= mean pressure, w= mean wedge pressure. 
 
Figure 2: The anteroposterior (A) and lateral (B) projections of an aortic root angiogram 
showing severe regurgitation of the calcified LV-AAo conduit.  
 
Figure 3: Artistic illustration depicting the hybrid surgical approach used to obtain 
procedural access. The proximal Dacron® tube graft is sutured at an oblique angle to the 
axillary artery to facilitate procedural access. The distal Dacron® tube graft was clamped 
and the anterior aspect of the graft was directly punctured for the catheterization. 
 
Figure 4:  Intraprocedural images showing the delivery of the Melody TPV® within the 
Endurant IITM stent graft (A), balloon dilation of the Melody valve (B) and proximal 
Endurant IITM stent graft (C) with a 20 mm balloon. The Endurant IITM stent graft is noted by 
the black arrows and Melody TPV® is noted by the white arrowheads.  
 
Figure 5: Final angiogram of the aortic root demonstrating no valvar regurgitation or peri-
valvar leak.  
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Figure 1: Illustrative diagram depicting the patient’s anatomy and hemodynamic measurements obtained 
during diagnostic catheterization. Ventricular pressures are noted as systolic/end diastolic pressure. m= 
mean pressure, w= mean wedge pressure.  
129x145mm (300 x 300 DPI)  
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Figure 2: The anteroposterior (A) and lateral (B) projections of an aortic root angiogram showing severe 
regurgitation of the calcified LV-AAo conduit.  
250x127mm (300 x 300 DPI)  
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Figure 3: Artistic illustration depicting the hybrid surgical approach used to obtain procedural access. The 
proximal Dacron® tube graft is sutured at an oblique angle to the axillary artery to facilitate procedural 
access. The distal Dacron® tube graft was clamped and the anterior aspect of the graft was directly 
punctured for the catheterization.  
148x145mm (300 x 300 DPI)  
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Figure 4:  Intraprocedural images showing the delivery of the Melody TPV® within the Endurant IITM stent 
graft (A), balloon dilation of the Melody valve (B) and proximal Endurant IITM stent graft (C) with a 20 mm 
balloon. The Endurant IITM stent graft is noted by the black arrows and Melody TPV® is noted by the white 
arrowheads.  
381x127mm (300 x 300 DPI)  
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Figure 5: Final angiogram of the aortic root demonstrating no valvar regurgitation or peri-valvar leak.  
130x130mm (300 x 300 DPI)  
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A 28 year-old male with single ventricular heart disease status post Fontan 
palliation and subsequent placement of left ventricle to ascending aorta (LV-AAo) valved 
conduit placement developed ascites and edema. Diagnostic catheterization revealed 
elevated ventr cular end diastolic pressures (EDP) secondary to severe LV-AAo conduit 
regurgitation. Given the unique anatomy, surgical access via the right axillary artery 
provided optimal route for transcatheter valve implantation (TVI) within the conduit. The 
procedure resulted in significant hemodynamic improvement with no complications.  
 
INTRODUCTION 
Single ventricle patients with declining or failing Fontan circulations often have 
limited interventional options for improving overall hemodynamics and functional status 
(1,2). The off-label use of FDA approved transcatheter valves provides a relatively new 
therapeutic option for patients with palliated complex congenital heart disease (3,4). We 
describe the innovative use of transcatheter valve implantation (TVI) in a failing Fontan 
patient using a novelhybrid surgical vascular access approach. 
 
CASE HISTORY 
A 28 year-old male with d-transposition of the great arteries, hypoplastic right 
ventricle (RV), ventricular septal defect (VSD) and straddling tricuspid valve underwent 
pulmonary artery banding at one year of age followed by a classic Fontan with pulmonary 
artery ligation at age 2.  Four years following his Fontan operation, the patient underwent 
placement of a 20 mm valved homograft conduit from the left ventricle to ascending aorta 
(LV-AAo) due to progressive severe restriction of the VSD and outflow to the aorta. At 22 
years of age, he developed multiple atrial arrhythmias and underwent a revision of his 
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Fontan with a 24 mm intra-atrial conduit, Maze procedure and placement of an epicardial 
pacemaker system. Preoperative catheterization prior to Fontan revision demonstrated no 
conduit regurgitation and minimal gradient (peak systolic ejection gradient 5 mmHg). As a 
result, the conduit was not replaced at that time. Six years following his Fontan revision, he 
developed symptoms of abdominal ascites and lower extremity edema. Given his new and 
progressive symptoms, the patient was referred to the catheterization laboratory where 
hemodynamic. Hemodynamic evaluation revealed mean Fontan pressures of 25 mmHg 
secondary to elevated RV and LV end diastolic pressures (EDP) of 22 and 21 mmHg, 
respectively. The peak systolic ejection gradient across the conduit was 10 mmHg (Figure 
1). The heavily and circumferentially calcified LV-AAo conduit had severe regurgitation 
(Figure 2). As theThe patient was an extremely high-risk surgical candidate secondary to his 
numerous prior sternotomies, high Fontan pressures, and severe diastolic dysfunction, and 
calcified conduit with close proximity to the sternum. As a result he was referred back to 
the catheterization laboratory two months later for TVI within the LV-AAo conduit.  
The LV-AAo conduit inserted on the leftward aspect of the ascending aorta following 
the lesser curve of the transverse arch. This created an almost 180 degree turn from the 
transverse arch to the distal insertion point of the LV-AAo conduit and precluded 
transcatheter valve delivery from a femoral arterial approach. In addition, the proximal LV-
AAo conduit takeoff was from the LV apex with an oblique orientation to the ventricle, 
which precluded transapical transcatheter delivery approach. Vascular surgery was 
consulted to provide access via the right axillary artery. Consent for off-label use of a 
humanitarian device was obtained. 
An 8 mm Dacron® tube graft was anastomosed at an oblique angle directly to the 
right axillary artery, which provided the most direct approach to the LV-AAo conduit via the 
right innominate artery (Figure 3). The distal end of the tube graft was clamped with a 
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vascular clamp for hemostasis and the catheterization was performed via direct puncture 
through the anterior aspect of the Dacron® graft. Once the conduit was accessed, a 20 mm x 
82 mm Endurant IITM stent graft (Medtronic, Minneapolis, MN) was inserted using the 16 
French Sentrant sheath (Medtronic, Minneapolis, MN). The stent graft was placed within the 
heavily calcified LV-AAo conduit prior to angioplasty to protect from potential catastrophic 
rupture of the conduit.secondary to its position within the high pressure systemic 
circulation. The stent graft also prevented potential calcific embolization/stroke as a result 
of anticipated aggressive conduit dilation. The calcified conduit created a very rigid tube 
which measured 18-20 mm along the entire course with little to no pulsatility. Therefore, 
we did not feel additional presenting was necessary and proceeded directly to TVI. A 
Melody Transcatheter Pulmonary Valve® (TPV) (Medtronic, Minneapolis, MN) was 
implanted within the LV-AAo conduit on a 20-mm Ensemble® Transcatheter Valve Delivery 
System (Medtronic, Minneapolis, MN) entirely within the distal end of the stent graft. There 
wasDue to the significant residual narrowing within the Melody TPV stent afterfollowing 
delivery, so the entire length of the stent graft and Melody valve was balloon dilated 
withusing a 20 mm x 2 cm Atlas Gold balloon (BARD Peripheral Vascular, Tempe, AZ) with 
effective relief of the stent narrowing (Figure 4). Post-procedural LV EDP dropped 
considerably to 10 mmHg and the LV-AAo conduit peak systolic ejection gradient was 
unchanged at 11 mmHg. Angiography demonstrated no residual LV-AAo conduit 
insufficiency and no perivalvar leak (Figure 5). The axillary artery access site was repaired 
and wound site closed. The patient tolerated the procedure well without complication and 
was discharged to home the following day. 
 
DISCUSSION  
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We report the first use of a transcatheter valve to treat a failing Fontan patient 
secondary to LV-AAo conduit insufficiency via a hybrid surgical approach. There are few 
publications describing transcatheter valve placement within the systemic semilunar valve 
position in patients with complex congenital heart disease (5-7). The approaches reported 
include percutaneous, hybrid transapical and, cutdown on the innominate artery. Though, 
and percutaneously via femoral or internal jugular veins. Given the patient’s unique 
anatomy precluded, a previously described route of transcatheter valve delivery, the 
innominate arteryhybrid surgical approach via a vascular graft provided an ideal approach 
for intervention in our patient. This approach has been utilized in adult patients to facilitate 
the implantation of transcatheter aortic valves and catheter-based Impella® left ventricular 
assist devices (ABIOMED, Inc. Danvers, MA) (8,9). In addition to limiting the injury of the 
axillary artery, the tube graft provided additional vascular length for manipulation of the 
100 cm long delivery system. 
The Melody TPV is made from a bovine jugular venous valve which has naturally 
deep commissures allowing for competency in non-circular outflow tracts. The valve is 
supported by a platinum/iridium frame which is highly malleable and can conform to 
irregular conduits (10). We were uncertain of the final configuration and long-term 
diameter of the heavily calcified LV-AAo conduit in this patient and felt the Melody TPV 
would function better than a Sapien Valve (Edwards Lifesciences Corporation, Irvine, CA) in 
a possible elliptical configuration and in a generally smaller outflow diameter. Conduit tear 
is a known risk for TVI and was the most common serious adverse event reported in the 
one-year follow-up of the Melody TPV multicenter Post-Approval Study (8)(11). Heavily 
calcified conduits are at risk for rupture and have been successfully treated with covered 
stents such as the covered Cheatham Platinum stent (NuMED Inc., Hopkinton, NY) (8-
10)(11-13).. The calcium deposits within the LV-AAo conduit circumscribed its entire length 
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and would have extended beyond a single covered stent. Deployment of the stent graft 
within ourthe patient’s conduit prior to Melody TPV implantationany intervention 
mitigated the bleeding risks from conduit rupture in the high pressure systemic circulation 
and protected against possible calcific embolization from the heavily calcified conduit. The 
stent graft was not used for typical Melody “pre-stenting” as is standardly performed in RV-
PA conduits. The conduit stenosis provided an optimal landing zone for the transcatheter 
valve remote from the coronary arteries. Our novelThe hybrid procedural approach coupled 
with the off-label use of the aortic stent graft and Melody TPV resulted in successful and 
uncomplicated treatment in this high-risk surgical patient.  
Although the Melody TPV has performed well relatively high pressure circulations, 
the long term durability is not known and remains a concern in these off-label uses 
(5,1114). With the development of smaller diameter and more easily steerable 
transcatheter delivery systems, future re-intervention from the percutaneous femoral 
arterial approach may be possible. However in the absence of this technology, a similar 
well-planned hybrid approach as described remains a viable option for TVI in patients with 
complex congenital heart anatomydisease. 
 
CONCLUSION 
Innovative off-label use of transcatheter valve therapy can be used to treat high-risk 
patients, including failing Fontan patients that have limited medical and surgical options. 
Novel hybridHybrid surgical approaches should be considered to provide the safest and 
most direct routes for TVI. 
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Figure 1: Illustrative diagram depicting the patient’s anatomy and hemodynamic 
measurements obtained during diagnostic catheterization. Ventricular pressures are noted 
as systolic/end diastolic pressure. m= mean pressure, w= mean wedge pressure. 
 
Figure 2: The anteroposterior (A) and lateral (B) projections of an aortic root angiogram 
showing severe regurgitation of the calcified LV-AAo conduit.  
 
Figure 3: Artistic illustration depicting the hybrid surgical approach used to obtain 
procedural access. The proximal Dacron® tube graft is sutured at an oblique angle to the 
axillary artery to facilitate procedural access. The distal Dacron® tube graft was clamped 
and the anterior aspect of the graft was directly punctured for the catheterization. 
 
Figure 4:  Intraprocedural images showing the delivery of the Melody TPV® within the 
Endurant IITM stent graft (A), balloon dilation of the Melody valve (B) and proximal 
Endurant IITM stent graft (C) with a 20 mm balloon. The Endurant IITM stent graft is noted by 
the black arrows and Melody TPV® is noted by the white arrowheads.  
 
Figure 5: Final angiogram of the aortic root demonstrating no valvar regurgitation or peri-
valvar leak.  
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